AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of April 4, 2025, AKTX stock price declined to $1.12 with 15,198 million shares trading.

AKTX has a beta of 0.91, meaning it tends to be less sensitive to market movements. AKTX has a correlation of 0.02 to the broad based SPY ETF.

AKTX has a market cap of $29.52 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AKTX traded as high as $32.20 and as low as $.85.

AKTX has underperformed the market in the last year with a price return of -22.6% while the SPY ETF was flat at -0.1%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.9% and -27.1%, respectively, while the SPY returned -14.4% and -10.4%, respectively.

AKTX support price is $1.09 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.